Right. By no means are they undervalued. March financials show that OCATA has no book value (will be a little improved for June, because of dilution). They are at least 5 years away for a Macular Degeneration product. From a financial point of view, the price should be lower. OCATA is at this price level because of their science, that may or may not get to phase 4 completion. Larger and more powerful companies may develop a better method eventually, and move quicker to develop the method, since they will have the resources and influence( and better management).Just IMO.